Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Genedrive extends global coverage with new distribution agreement in India

The AIM-listed diagnostics manufacturer said the agreement will focus on securing regulatory approvals for its HCV ID Kit in India
Scientist using microscope
Genedrive said it would retain responsibility for product development, quality management and manufacturing

Genedrive PLC (LON:GDR) has signed a new distribution agreement for its Genedrive HCV ID Kit and Genedrive platform in India.

The AIM-listed diagnostics manufacturer said the agreement made with ARKRAY Healthcare pvt Ltd (ARKRAY), a subsidiary of ARKRAY Inc. Japan, will focus on securing regulatory approvals for the HCV ID Kit in India.

READ: Genedrive continues to execute on its strategy to focus fully on molecular diagnostics

Genedrive added that it would retain responsibility for product development, quality management and manufacturing, with commercial activities expected to begin in the latter part of its 2018/19 financial year.

ARKRAY will be responsible for sales, marketing, customer support and distribution activities across the region, the group said.

The development is another step in the firms push into global commercial territory, having begun commercial sales and shipments of its HCV ID Kit into the EMEA region in mid-March.

David Budd, Genedrive chief executive, said: "We are extremely pleased to extend our commercial reach into India with ARKRAY, who have established an extensive and respected diagnostic sales and support business in the Indian market. This agreement provides access to another important and very relevant region for Genedrive through a world class commercial partner."

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

July 02 2018
The research and diagnostic company develops cancer-detecting blood tests
June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use